Thermo Fisher Scientific is a global provider of laboratory instruments, reagents and services supporting life‑sciences research and diagnostics, characterized by high gross and operating margins and consistent cash generation across recent periods.
The company’s profitability profile is strong: gross margin reached 69.9% and operating margin 50.3% in the most recent period, with net profit margin around 15.0% (Profit Margin Trends).
Top‑line per‑share growth has recovered, with a five‑year revenue‑per‑share CAGR of 6.70% and revenue per share rising to $117.87 most recently while diluted EPS reached $17.74 (EPS Diluted & Revenue per Share).
Cash generation underpins earnings quality: trailing twelve‑month operating cash flow was $7.82B versus net income of $6.70B (a \$1.12B cash/earnings gap), free cash flow margin is about 15.39%, and the cash conversion ratio sits at 1.34, indicating OCF generally exceeds reported earnings (Earnings Quality Analysis; Revenue & Net Income).
There are areas of concern to monitor. Return on equity has weakened modestly: ROE settled at 12.6% most recently after 13.2% earlier in 2025 and ROE growth is negative at -1.8% (actual -0.0180), reflecting declining returns on shareholder equity (Return on Equity (ROE)).
Operating cash flow has also retreated from $9.35B in mid‑2024 to 7.82B as of 2025‑12‑31, while investing cash flow remains a persistent outflow (-\$4.05B TTM investing cash flow), narrowing the buffer between cash from operations and capital deployment (Strategic Capital Allocation; Earnings Quality).
Key fundamentals to watch going forward include the trend in operating cash flow versus net income and the cash/earnings gap, quarterly revenue‑per‑share and diluted EPS growth rates (recent 1‑year figures: revenue per share +3.9%, EPS +5.8%), free cash flow margin and investing cash outlays, the trajectory of ROE around the current ~12.6% level, and the company’s trailing P/E which was 32.7x at the most recent quarter (Revenue & Net Income; EPS Diluted & Revenue per Share; Earnings Quality; Return on Equity (ROE); Price-to-Earnings (PE) Ratio Trend).
The foundation of business quality and long-term value creation
THERMO FISHER SCIENTIFIC INC.'s most recent fiscal year shows a clear upward trend through 2025: quarterly revenue rose sequentially from $10.36B (2025 Q1) to $10.86B (Q2), $11.12B (Q3) and $12.21B (Q4), while net income moved from $1.51B to $1.62B, $1.62B and $1.96B over the same quarters. These 2025 quarter-to-quarter increases represent the strongest recent acceleration in both top-line and bottom-line figures, with the largest single-quarter gain occurring in revenue in 2025 Q4 and a corresponding net income uptick in that quarter.
Over the multi-year series, revenue has risen from approximately $6.08B in early 2018 to $12.21B in 2025, and net income has exhibited higher volatility with notable spikes (for example $4.00B in 2021 Q4 and $2.50B in 2020 Q4) amid generally positive levels in 2023–2025 around $1.3B–$1.9B. The most recent quarterly revenue was $12.21B and the most recent quarterly net income was $1.96B.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Over the period Jan 2025 to Dec 2025, Thermo Fisher Scientific Inc converts approximately 70¢ of every revenue dollar into gross profit (gross margin: 69.9%).After accounting for operating expenses and taxes and expenses, the company retains 15.0% as net profit margin, resulting in $6.70B in net earnings.
Period Information
Report Type: Annual (10-K)
Period: Jan 2025 to Dec 2025
Revenue composition by disclosure category for the latest period
reagents, instruments and consumables for biological and medical research, drug and vaccine discovery and production, and diagnosis of disease; biosciences reagents, instruments and consumables for molecular and protein biology research and diagnostics; genetic sciences instruments and related reagents for genomic and proteomic solutions; bioproduction solutions and services for production of biologics and industrial manufacturing, including upstream cell culture, downstream purification, analytics, filtration and separation, and single-use solutions across the biologics workflow.
analytical instruments and supporting consumables, software and services for organic and inorganic sample analysis, process and production monitoring, field and safety testing, environmental and process instruments, and electron microscopy tools and integrated workflows for life sciences, materials sciences and semiconductor research and production.
diagnostic test kits, reagents, culture media, instruments and associated products for healthcare, clinical, pharmaceutical, industrial and food safety laboratories; clinical diagnostics reagent kits, calibrators, controls, protein detection assays and instruments; immunodiagnostic blood-test systems; microbiology culture media, collection and transport systems, instrumentation and consumables, diagnostic and rapid direct specimen tests, and quality-control products; transplant diagnostics for human leukocyte antigen typing; a healthcare market channel offering consumables, diagnostic kits, reagents, equipment, instruments, solutions and services for hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.
laboratory consumables, equipment and chemicals for life science research and drug discovery; a mix of self-manufactured, private-label and third-party branded products offered through market channels; outsourced services for drug development, clinical research, clinical trials services and commercial drug manufacturing; pharma services covering development, manufacturing and clinical trials services for small-molecule and large-molecule pharmaceuticals; clinical research services providing integrated clinical development and analytical services across all phases of development, peri- and post-approval support, and site and patient access services.
Pharmaceutical and biotechnology companies; hospitals and clinical diagnostic laboratories; universities and academic research institutions; government agencies; clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities; environmental, industrial, research and development, quality and process control settings; materials and semiconductor research and production customers; applied markets and other industrial markets.
Global operations and channels with presence across the Americas, Asia-Pacific, and Europe, Middle East and Africa regions. The company markets and delivers products and services worldwide through a global team and brands.
Direct sales force and customer-service professionals, including technically trained specialists; electronic commerce; third-party distributors. Sales and services are delivered through company brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company also provides product standardization and supply-chain-management services to customers.
The company offers outsourced services for drug development, clinical research, clinical trials services and commercial drug manufacturing and provides integrated clinical development and analytical services including peri- and post-approval and site and patient access services. The company sells capital equipment and seasonal diagnostic products, and notes that sales of seasonal products vary quarter to quarter and year to year and that fourth-quarter revenues have historically been stronger due to customer capital spending patterns. The company provides product standardization and supply-chain-management services to customers.
Certain materials or components may be sourced from a single supplier or a limited number of suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. The company has agreements to sell products and services to government entities and is subject to laws and regulations that apply to government contracting; noncompliance could result in reductions in revenues from these customers or other penalties. The company is subject to environmental remediation obligations at specific sites and records accruals for environmental liabilities; future remedial or compliance costs could have an adverse effect. The company operates in markets subject to complex regulatory requirements governing development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and similar products and is subject to export, import, logistics and data privacy and AI-related regulatory regimes. The company faces aggressive competition in virtually all markets served. Patents are important in many aspects of the business, and the company seeks patent protection and uses trade secrets and licensing arrangements where appropriate.
Analyzing long-term margin stability and competitive positioning
THERMO FISHER SCIENTIFIC INC.'s net profit margin has shown a gradual upward trend over the past two years, rising from about 13.2% in mid-2023 to a band around 15.0–15.2% through 2024–2025, with the most recent quarters at 15.2% (2025-03 and 2025-06) and 15.0% (2025-09 and 2025-12).
Gross margin and operating margin display larger swings in the historical series: gross margin is 69.9% in the latest quarter after earlier readings that ranged widely (notably ~17% in early/mid-2023 and 58–65% in 2021–2022).
Operating margin moved from negative territory in parts of 2022–2023 (e.g., -3.0% in 2023-04 and 2023-07) to materially positive levels in later periods, reaching 50.3% in the latest quarter.
Net margin improvement has been steadier and less volatile than the other two metrics over the most recent quarters.
Latest values (period ending 2025-12-31): Gross Margin 69.9%, Operating Margin 50.3%, and Net Profit Margin 15.0%.
Understanding Profit Margins
Between Jan 2025 and Dec 2025, Thermo Fisher Scientific Inc converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
Over the most recent year the trailing-twelve-month series shows operating cash flow declining while net income has been relatively stable to slightly higher. From mid‑2024 through the end of 2025 operating cash flow fell from $9.35B () to $7.82B (), while net income moved from $6.18B to $6.70B over the same span. As a result the operating cash flow has remained above net income but the cash/earnings gap narrowed to $1.12B in the most recent period.
Looking farther back, operating cash flow has generally exceeded net income across many periods, though there was a clear inflection in 2022 when several trailing‑twelve‑month readings (, , ) showed net income ($9.95B, $9.79B, $9.38B) exceeding operating cash flow ($9.54B, $8.84B, $8.12B). Since those peaks both metrics have trended lower into 2024–2025. The most recent trailing-twelve-month operating cash flow was $7.82B. The most recent trailing-twelve-month net income was $6.70B.
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
Trailing Twelve Months
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
THERMO FISHER SCIENTIFIC INC.'s trailing twelve-month Return on Equity has been in a narrow band around 12–13% through 2024–2025, with quarter-to-quarter values of 13.2% (2025-03-29), 13.0% (2025-06-28), 12.9% (2025-09-27) and most recently 12.6% (2025-12-31), indicating a modest decline across the last three quarters of 2025. The series shows relative stability in the low-teens over the most recent year, with the latest quarter at the lower end of that range.
Looking back, ROE rose from low single digits in the early 2010s into the mid-to-high teens by 2020 and peaked above 24% in 2021 (24.3% on 2022-04-02), before declining through 2022 into the mid-teens (15.8% on 2022-12-31) and settling into the current ~12–13% range across 2023–2025. The most recent reported Return on Equity was 12.6% as of the period ending 2025-12-31.
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
THERMO FISHER SCIENTIFIC INC.'s trailing‑12‑month operating cash flow has moved lower over the last year, retreating from $8.67B at to $7.82B at , with intermediate TTM readings of $8.14B (), $7.58B (), and $7.65B (). Investing cash flow has been consistently negative (cash outflows) but has moderated versus prior quarters, easing from -$5.84B at to -$4.05B at after TTM values of -$4.34B, -$4.37B and -$4.92B through .
Financing activity shows a notable inflection in the most recent TTM: financing cash flow was negative across several quarters (for example -$6.79B at and -$5.39B at ) but turned positive to $1.80B as of . The most recent TTM values were: operating cash flow $7.82B, investing cash flow -$4.05B, and financing cash flow $1.80B.
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Trailing Twelve Months
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
THERMO FISHER SCIENTIFIC INC.'s trailing twelve‑month price‑to‑earnings ratio narrowed mid‑year 2025 before rebounding into year‑end. The P/E fell to 23.3x for the quarter ended 2025‑06‑28, then rose to 26.6x in the quarter ended 2025‑09‑27 and to 32.7x in the quarter ended 2025‑12‑31, slightly above the prior year‑end reading of 31.0x.
Over the fuller history shown, the P/E has most often traded in the mid‑20s to mid‑30s, with notable highs such as 38.2x (2024‑09‑28) and lows including 10.3x (2011‑10‑01). The most recent quarterly P/E ratio was 32.7x (period end 2025‑12‑31).
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.